Beam Therapeutics
(NASDAQ) BEAM
Beam Therapeutics Financials at a Glance
Market Cap
$2.43B
Revenue (TTM)
$139.74M
Net Income (TTM)
$79.99M
EPS (TTM)
$-1.02
P/E Ratio
-23.46
Dividend
$0.00
Beta (Volatility)
2.03 (High)
Dividend
$0.00
Beta (Volatility)
2.03 (High)
Price
$24.26
Volume
2,088,058
Open
$24.02
Price
$24.26
Volume
2,088,058
Open
$24.02
Previous Close
$24.22
Daily Range
$24.02 - $25.30
52-Week Range
$13.53 - $36.44
Dividend
$0.00
Beta (Volatility)
2.03 (High)
Price
$24.26
Volume
2,088,058
Open
$24.02
Previous Close
$24.22
Daily Range
$24.02 - $25.30
52-Week Range
$13.53 - $36.44
BEAM News
BEAM: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Beam Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
511
CEO
John Evans, MBA
Website
www.beamtx.comHeadquarters
Cambridge, MA 02142, US
BEAM Financials
Key Financial Metrics (TTM)
Gross Margin
-1%
Operating Margin
-3%
Net Income Margin
-57%
Return on Equity
-8%
Return on Capital
-28%
Return on Assets
-5%
Earnings Yield
-4.26%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.43B
Shares Outstanding
101.86M
Volume
2.09M
Short Interest
0.00%
Avg. Volume
2.00M
Financials (TTM)
Gross Profit
$117.45M
Operating Income
$383.69M
EBITDA
$29.92M
Operating Cash Flow
$345.10M
Capital Expenditure
$14.95M
Free Cash Flow
$360.05M
Cash & ST Invst.
$1.25B
Total Debt
$293.88M
Beam Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$114.11M
+279.5%
Gross Profit
$108.44M
+251.9%
Gross Margin
95.03%
N/A
Market Cap
$2.43B
N/A
Market Cap/Employee
$6.18M
N/A
Employees
393
N/A
Net Income
$244.30M
+370.4%
EBITDA
$260.61M
+375.5%
Quarterly Fundamentals
Net Cash
$951.33M
+38.0%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$279.52M
+88.9%
Short Term Debt
$14.36M
+6.6%
Return on Assets
-5.40%
N/A
Return on Invested Capital
-27.72%
N/A
Free Cash Flow
$87.02M
-9.7%
Operating Cash Flow
$83.29M
-9.1%